Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130531 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
A Phase 1 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02130531 is a Phase 1 study that has completed, run by Kubota Vision. The registered enrollment target is 26 participants.
The verdict
NCT02130531, a Phase 1 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
Interventions
- OTHER Placebo Tablet
- DRUG Emixustat HCl Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02130531
The ClinicalTrials.gov registry entry for NCT02130531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Tablet is the first listed.
NCT02130531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02130531 about?
NCT02130531 is a clinical study titled "Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration". The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
What is the current status of trial NCT02130531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02130531?
The interventions under investigation include: Placebo Tablet (OTHER), Emixustat HCl Tablet (DRUG).
Who is sponsoring clinical trial NCT02130531?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.